Abstracts tagged "Nephritis"

Abstract Number: 0355 • ACR Convergence 2022
Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study
Amit Saxena¹, Dawn Caster², Salem Almaani³, Amber Rosales⁴ and Henry Leher⁵, ¹NYU School of Medicine, New York, NY, ²University of Louisville, Louisville, KY, ³The Ohio State University Medical Center, Columbus, OH, ⁴Aurinia Pharmaceuticals Inc., Rockville, MD, ⁵Aurinia Pharmaceuticals Inc, Rockville, MD
Background/Purpose: Persistent proteinuria increases the risk of comorbidities in lupus nephritis, and rapid reductions in protein have shown to be predictive of improved long-term renal…
Abstract Number: 0362 • ACR Convergence 2022
The Renal Activity Index for Lupus (RAIL) Identifies Active Renal Disease in SLE Patients and Its Longitudinal Score Associates with Renal Responses in Lupus Nephritis
Hermine I. Brunner¹, Catharina Lindholm², Ellen Cody¹, Prasad Devarajan¹, Bin Huang¹, Dominic Sinibaldi³, Madhu Ramaswamy³, Jacob Knagenhjelm⁴, Tingting Qiu¹, Frederick Jones⁵, Philip Brohawn³, Raj Tummala³ and Wendy White³, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²AstraZeneca, Gothenburg, Sweden, ³AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Gateborg, Sweden, ⁵AstraZeneca, Cambridge, United Kingdom
Background/Purpose: LN confers poor prognosis, and there is a lack of effective non-invasive tests to assess disease activity and treatment response. We previously showed that…
Abstract Number: 0443 • ACR Convergence 2022
Prognosis of Non-PR3 ANCA-Associated Vasculitis with Glomerulonephritis
Aurélien Chepy¹, Hélène Béhal², Alexandre Karras³, Xavier Puéchal⁴, Benjamin Terrier⁴, David Jayne⁵, Thomas Quéméneur⁶ and Mary-Jane Guerry⁷, ¹CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ²University of Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des Technologies de Santé et des Pratiques Médicales, Lille, France, ³HEGP, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁵University of Cambridge, Cambridge, United Kingdom, ⁶Valenciennes Hospital, Valenciennes, France, ⁷Department of Nephrology, Centre Hospitalier de Valenciennes, Valenciennes., Valenciennes, France
Background/Purpose: Immunosuppressive treatments have improved the prognosis of anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), transforming these formerly fatal diseases into chronic conditions, with periods of…
Abstract Number: 1476 • ACR Convergence 2022
Anti-Neutrophil Extracellular Traps (NET) Antibodies and Their Association with Disease Activity and Clinical Phenotypes in Systemic Lupus Erythematosus
Rosa Arvizu-Rivera¹, jiram torres-Ruiz², Alfredo Pérez-Fragoso², Beatriz Alcalá-Carmona³, Miroslava Nuñez-Aguirre⁴, Ana Sofía Vargas-Castro⁴, Abdiel Absalón-Aguilar³, Jaquelin Lira-Luna⁴ and Diana Gómez-Martín², ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de México, Mexico, ²INCMNSZ, Ciudad de México, Mexico, ³Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, ⁴Instituto Nacional de Ciencias Medicas y Nutricion "Salvador Zubiran", Ciudad de México, Mexico
Background/Purpose: Enhanced netosis has been acknowledged as pathogenic in Systemic Lupus Erythematosus (SLE). The presence of antibodies against neutrophil extracellular traps (anti-NETs) in patients with…
Abstract Number: 1665 • ACR Convergence 2022
The TLR7/8 Inhibitor Enpatoran Reverses Established Kidney Disease in the Interferon-Alpha-Accelerated NZB/W Mouse Model of Lupus
Julia Bruttger¹, Andrew Bender², Sonja Reissig¹, Amy Kao³ and Philipp Haselmayer¹, ¹the healthcare business of Merck KGaA, Darmstadt, Germany, ²TIP Immunology, EMD Serono, Billerica, MA, ³EMD Serono, Billerica, MA
Background/Purpose: Activation of toll-like receptor 7 and 8 (TLR7/8) signaling by single-stranded RNA results in immune cell stimulation and inflammatory cytokine production, a normal circumstance…
Abstract Number: 1697 • ACR Convergence 2022
Measurements of Specific Activation Through the Lectin -or Classical Pathway of Complement in Patients with SLE
Anne Troldborg¹, Mads Lamm Larsen¹, Erik J.M. Toonen², Lisa Hurler³, Zoltan Prohaszka³, László Cervenak³, Annette Gudmann Hansen⁴ and Steffen Thiel⁴, ¹Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Hycult Biotech, Arnhem-Nijmegen, Netherlands, ³Semmelweis University, Budapest, Hungary, ⁴Aarhus University, Aarhus, Denmark
Background/Purpose: In systemic lupus erythematosus (SLE), the complement system is activated and commonly thought to occur through the classical pathway (CP) [1]. However, our previous…
Abstract Number: 0304 • ACR Convergence 2021
Renal Involvement in Sjőgren’s Syndrome: Predictors and Impact on Patient Outcome
Rudrarpan Chatterjee¹, Anu Balakrishnan², Rajat Kharbanda¹, Upendra Rathore¹, Latika Gupta¹, Durga P Misra¹, Vikas Agarwal², Amita Aggarwal¹ and Able Lawrence², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Renal disease in primary Sjogren's syndrome (pSS) can occur in form of tubulointerstitial nephritis (TIN) or glomerulonephritis (GN). Data from India on pSS is…
Abstract Number: 0472 • ACR Convergence 2021
An Atlas of Human and Mouse Intrarenal Immune Cells in Lupus Nephritis Reveals Homologous Immune Populations Across Common Mouse Strains and Species
Paul Hoover¹, Michael Peters², David Lieb², Runci Wang³, Garett Dunlap⁴, Deepak Rao¹, Nir Hacohen² and Anne Davidson⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Broad Institute, Cambridge, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Harvard University, Somerville, MA, ⁵Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: We discovered 21 immune cell-types in lupus nephritis kidney biopsies as part of the Accelerating Medicines Partnership (AMP) consortium. These immune cells are the…
Abstract Number: 1503 • ACR Convergence 2021
Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging
Craig Smuda¹, Anna Eichinger², Robert Clancy², Jill Buyon³ and Boris Reizis⁴, ¹NYU Grossman School of Medic ine, New York, NY, ²NYU Grossman School of Medicine, New York, NY, ³NYU School of Medicine, New York, NY, ⁴New York University Grossman School of Medicine, New York, NY
Background/Purpose: The Accelerating Medicines Project (AMP) has enabled significant increases in understanding of SLE nephritis pathology, providing a profile of dozens of leukocyte subsets within…
Abstract Number: 0035 • ACR Convergence 2020
Distinct Biological Pathways in Both Blood and Kidney Further Define Molecular Profiles Across Diverse Nephritides
Loqmane Seridi¹, Matteo Cesaroni¹, Qingxuan Song², Ashley Orillion¹, Frédéric Baribaud¹, Tatiana Ort¹, Sheng Gao², Tomas Parker³, James Chevalier³, Dan Levine³, Alan Perlman³ and Jarrat Jordan¹, ¹Janssen Research & Development, LLC, Spring House, PA, ²Janssen Research & Development, LLC, Spring House, PA, USA, Spring House, PA, ³The Rogosin Institute, New York Presbyterian Hospital-Weill Medical College of Cornell University New York, NY, USA., New York, NY
Background/Purpose: Approximately 40% of SLE patients will develop Lupus Nephritis (LN), of which 10-30 % will progress to end-stage renal disease. To further understand LN…
Abstract Number: 0257 • ACR Convergence 2020
Application of Text Mining Methods to Identify Lupus Nephritis from Electronic Health Records
Milena Gianfrancesco¹, Suzanne Tamang², Gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹University of California, San Francisco, San Francisco, CA, ²Stanford Center for Population Health Sciences, Redwood City, CA, ³University of California, San Francisco, Atherton, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Lupus nephritis (LN) is a frequent complication of SLE and associated with higher morbidity and mortality. Accurate estimates of the prevalence of LN in…
Abstract Number: 0261 • ACR Convergence 2020
Predictors of Future Repeat Renal Biopsies in Patients with Lupus Nephritis and Influence of Repeat Biopsy in Flare Management: A Retrospective Study
Rosalba Santana-Flores¹, Anitha Ramu¹, Hana Rajevac² and Belinda Jim³, ¹Jacobi Medical Center at Albert Einstein College of Medicine, BRONX, NY, ²James J Peters Medical Center, NEW YORK, NY, ³Jacobi Medical Center at Albert Einstein College of Medicine, New Hyde Park, NY
Background/Purpose: Repeat renal biopsies are considered in patients with Lupus Nephritis (LN) flares or with failure of response to treatment. The influence of repeat renal…
Abstract Number: 0303 • ACR Convergence 2020
SLE Patients Stratify into Distinct Clusters Based on Their Peripheral Blood Immunologic Phenotype During Acute Flare
Kieran Manion¹, Carolina Munoz-Grajales², Michael Kim³, Kirubel Goliad⁴, Dennisse Bonilla⁵, Dafna Gladman¹, Murray Urowitz⁶, Zahi Touma⁷ and Joan Wither⁵, ¹Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto-UHN, Toronto, ON, Canada, ³Krembil Research Insitute, Toronto, ON, Canada, ⁴University of Toronto-UHN, Toronto, Canada, ⁵University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁶University Health Network, University of Toronto, Toronto, ON, Canada, ⁷University of Toronto, Toronto, ON, Canada
Background/Purpose: SLE is a chronic autoimmune disease in which periods of quiescence are interspersed with acute flares of disease activity that produce much of the…
Abstract Number: 0497 • ACR Convergence 2020
Interleukin-23 Acts Directly on Podocytes and Contributes to the Development of Glomerulonephritis
Shui Lian Yu¹, Hao Li¹, Abhigyan Satyam¹, Shawn Rose², Jarrat Jordan³ and George Tsokos⁴, ¹Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, boston, ²Rheumatology & Autoimmunity Translational Medicine at Janssen Pharmaceuticals, boston, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Division of Rheumatology & Clinical Immunology/Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA
Background/Purpose: Interleukin (IL)-23 is central in the advancement of an inflammatory response and has been shown to be involved in the pathogenesis of autoimmune diseases.…
Abstract Number: 0837 • ACR Convergence 2020
Deletion of miR-223 Exacerbates Lupus Nephritis by Targeting S1pr1 in Faslpr/lpr Mice
Sumie Hiramatsu Asano¹, Tomoyuki Mukai², Yoshitaka Morita³ and Jun Wada⁴, ¹Kawasaki Medical School/Department of Rheumatology, Kurashiki city, Japan, ²Kawasaki Medical School, Kurashiki-shi, Okayama, Japan, ³Kawasaki Medical School/Department of Rheumatology, Kurashiki, Okayama, Japan, ⁴Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences., Okayama city, Japan
Background/Purpose: To identify new candidate genes regulated by micro RNAs (miRNAs) and involved in the pathogenesis of systemic lupus erythematosus (SLE), we integrated miRNA and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].